Venus Concept Inc. (NASDAQ:VERO) Short Interest Update

Venus Concept Inc. (NASDAQ:VERO) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 80,800 shares, a growth of 54.8% from the August 31st total of 52,200 shares. Based on an average trading volume of 363,200 shares, the days-to-cover ratio is presently 0.2 days. Currently, 5.5% of the company’s shares are sold short. Currently, 5.5% of the company’s shares are sold short. Based on an average trading volume of 363,200 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Venus Concept in a research note on Saturday, September 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Venus Concept Trading Up 1.3%

Shares of VERO opened at $2.33 on Tuesday. The firm’s 50-day moving average price is $2.36 and its 200-day moving average price is $2.61. The firm has a market capitalization of $3.31 million, a price-to-earnings ratio of -0.05 and a beta of 0.05. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 5.72. Venus Concept has a 1-year low of $2.10 and a 1-year high of $14.50.

Venus Concept (NASDAQ:VERO) last announced its earnings results on Thursday, August 14th. The company reported ($8.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.72) by $1.69. Venus Concept had a negative net margin of 68.77% and a negative return on equity of 871.77%. The firm had revenue of $15.69 million for the quarter, compared to analyst estimates of $14.01 million.

About Venus Concept

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.